Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Ken ichiro Shiga"'
Autor:
Shigetomo Yamada, Masaki Shiota, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Publikováno v:
Prostate International, Vol 10, Iss 1, Pp 50-55 (2022)
Background: Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide have been shown to prolong survival in patients with advanced prostate cancer. However, there is limited evidence on the anticancer effect of a reduced dose
Externí odkaz:
https://doaj.org/article/bf0c9b5ed77f474e89a68a8d22bbbe84
Autor:
Sotaro Chikamatsu, Masaki Shiota, Shigetomo Yamada, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Publikováno v:
Prostate International, Vol 10, Iss 1, Pp 7-13 (2022)
Background: The CHAARTED and LATITUDE trials demonstrated a survival benefit of docetaxel and abiraterone for hormone-sensitive prostate cancer. In this study, we examined the impact of the risk stratification criteria used in the CHAARTED and LATITU
Externí odkaz:
https://doaj.org/article/8610c69ac79a467c98ae471751c6ee74
Autor:
Eiji Kashiwagi, Leandro Blas, Kosuke Ieiri, Takashi Matsumoto, Ario Takeuchi, Masaki Shiota, Shigehiro Tsukahara, Masatoshi Eto, Akira Yokomizo, Ken ichiro Shiga, Junichi Inokuchi, Shohei Nagakawa
Publikováno v:
Anticancer Research. 41:5593-5598
BACKGROUND/AIM To explore the prognostic value of lower urinary tract symptoms (LUTS) in patients with newly diagnosed regional lymph node-positive prostate cancer. PATIENTS AND METHODS The prognostic value of LUTS for progression-free (PFS) and over
Autor:
Masaki Shiota, Sotaro Chikamatsu, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Publikováno v:
Journal of Urology. 207
Autor:
Keisuke Monji, Ario Takeuchi, Ryosuke Takahashi, Junichi Inokuchi, Satoshi Kobayashi, Masatoshi Eto, Takashi Matsumoto, Masaki Shiota, Asako Machidori, Akira Yokomizo, Eiji Kashiwagi, Ken ichiro Shiga, Takuya Yamashita
Publikováno v:
Cancer Investigation. 39:251-256
We investigated the efficacy and safety profiles of 4-weekly docetaxel for castration-resistant prostate cancer. Patients treated with ≥2 courses of docetaxel chemotherapy (median, 70 mg/m2) betwee...
Autor:
Masaki Shiota, Eiji Kashiwagi, Seiji Naito, Akira Yokomizo, Nobuaki Sato, Masatoshi Eto, Ken ichiro Shiga, Junichi Inokuchi, Ario Takeuchi
Publikováno v:
Cancer Investigation. 38:559-564
We analyzed the association between smoking and oncological outcome after radical prostatectomy with neoadjuvant hormonal therapy. This study included men who had undergone radical prostatectomy with neoadjuvant hormonal therapy between 2003 and 2016
Autor:
Takashi, Matsumoto, Masaki, Shiota, Shigetomo, Yamada, Leandro, Blas, Hidekazu, Naganuma, Ken, Lee, Keisuke, Monji, Eiji, Kashiwagi, Ario, Takeuchi, Junichi, Inokuchi, Ken-Ichiro, Shiga, Akira, Yokomizo, Masatoshi, Eto
Publikováno v:
JMA journal. 5(1)
Studies on the effect of androgen receptor pathway inhibitors (ARPI), docetaxel (DTX), and radium-223 (Ra-223) after first-line treatment with ARPI in patients with castration-resistant prostate cancer (CRPC) are scarce. This study compared the effic
Autor:
Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Masaki Shiota, Ario Takeuchi, Junichi Inokuchi, Satoshi Kobayashi, Akira Yokomizo, Masatoshi Eto, Ken ichiro Shiga
Publikováno v:
International journal of urology : official journal of the Japanese Urological AssociationReferences. 29(1)
OBJECTIVES To investigate predictive factors of survival of metastatic castration-resistant prostate cancer patients undergoing first-line treatment with androgen receptor pathway inhibitors or docetaxel. METHODS Japanese patients with metastatic cas
Autor:
Shohei Ueda, Ario Takeuchi, Akira Yokomizo, Satoshi Kobayashi, Eiji Kashiwagi, Keisuke Monji, Masaki Shiota, Mikifumi Koura, Junichi Inokuchi, Ken ichiro Shiga, Takashi Matsumoto, Masatoshi Eto
Publikováno v:
Japanese journal of clinical oncology. 51(7)
Objective This study aimed to reveal the prognostic values of prior local therapy in first-line therapy using androgen receptor-axis targeting agents (abiraterone or enzalutamide) or docetaxel for castration-resistant prostate cancer (CRPC). Methods
Autor:
Ryosuke Takahashi, Masaki Shiota, Eiji Kashiwagi, Ario Takeuchi, Hidenori Iwai, Tadamasa Yoshitake, Hiromi Terashima, Masatoshi Eto, Kosuke Ieiri, Yoshiyuki Shioyama, Junichi Inokuchi, Kousei Ishigami, Akira Yokomizo, Ken ichiro Shiga
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 38:931.e1-931.e7
Background This study aimed to identify the prognostic and predictive factors of local radiotherapy in clinically regional lymph node-positive prostate cancer. Patients and Methods This study includes patients who were newly diagnosed with regional l